

1 **Relative vaccine effectiveness of a CoronaVac booster dose in preventing symptomatic SARS-CoV-2**  
2 **infection among healthcare workers during an Omicron period in Azerbaijan, January–August 2022**

3 Iris Finci<sup>1\*</sup>, Madelyn Yiseth Rojas Castro<sup>2\*</sup>, Nabil Seyidov<sup>3\*</sup>, Samir Mehdiyev<sup>3</sup>, C. Jason McKnight<sup>1</sup>,  
4 Barbara Mühlemann<sup>4,5</sup>, Christian Drosten<sup>4,5</sup>, Lindsey Duca<sup>6</sup>, Richard Pebody<sup>1</sup>, Esther Kissling<sup>2</sup>, Mark A.  
5 Katz<sup>1</sup>, Gahraman Hagverdiyev<sup>3</sup>

- 6 1. World Health Organization Regional Office for Europe, Copenhagen, Denmark
- 7 2. Epiconcept, Paris, France
- 8 3. Public Health and Reforms Center, Ministry of Health, Azerbaijan Republic
- 9 4. Institute of Virology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität  
10 Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany
- 11 5. German Centre for Infection Research (DZIF), partner site Charité, 10117 Berlin, Germany
- 12 6. United States Centers for Disease Control and Prevention, Atlanta, GA, United States of America

13 \* These first authors contributed equally to this article

14

15 Corresponding author:

16 Iris Finci

17 World Health Organization Regional Office for Europe

18 UN City, Marmorvej 51, 2100 Copenhagen, Denmark

19 [fincii@who.int](mailto:fincii@who.int)

20

21 Abstract word count: 50

22 Main text word count: 1180

23 **Key words:** Azerbaijan, CoronaVac, COVID-19, healthcare workers, SARS-CoV-2, booster, vaccination,  
24 vaccine effectiveness, BA.1, BA.2, Omicron

25

26 **Abstract**

27 Among Azerbaijani healthcare workers (HCWs), compared to primary vaccine series, CoronaVac  
28 booster relative vaccine effectiveness was 60% (95% CI:25–79) and 79% (95% CI:44–92) against  
29 symptomatic and medically attended illness, respectively, during an Omicron BA.1/BA.2 period. Our  
30 results support timely CoronaVac booster uptake among Azerbaijani HCWs to reduce morbidity.

31

32

33

34

35

36

37

38

39

40

41

42

## 43 **Main text**

44 COVID-19 vaccination has been critical in reducing COVID-19-related morbidity and mortality (1,2).  
45 Vaccinating healthcare workers (HCWs) against COVID-19 is vital for more resilient healthcare systems;  
46 HCWs face high SARS-CoV-2 exposure, regularly interact with vulnerable patients, and are essential for  
47 the continuous functioning of health services. In Azerbaijan, an upper-middle income country, HCWs  
48 have been prioritized for COVID-19 vaccination throughout the vaccination campaign. CoronaVac  
49 (CN02 strain, Sinovac, Beijing) has mainly been used. While inactivated vaccines like CoronaVac have  
50 been widely used in low- and middle-income countries, including those in the WHO European Region,  
51 few studies have evaluated their effectiveness, particularly during the period characterised by  
52 circulation of Omicron variants BA.1, BA.2 and BA.4/5 (hereafter 'Omicron period') (3–8).

53 Understanding COVID-19 vaccine effectiveness is essential for guiding vaccine policy. Additionally,  
54 having local data showing effectiveness of COVID-19 vaccines can help promote vaccine uptake. Using  
55 a prospective cohort of HCWs in Azerbaijan, we previously estimated that vaccine effectiveness (VE) of  
56 two-dose primary vaccine series (PVS) against symptomatic SARS-CoV-2 infection was 19% during a  
57 Delta-predominant period (9). In this study, we the same cohort to estimate relative VE (rVE) of a  
58 CoronaVac booster dose compared to PVS against symptomatic SARS-CoV-2 infection during an  
59 Omicron-predominant period.

60

## 61 **The study**

62 This cohort study has been described previously (9,10). Briefly, in mid-2021, we enrolled HCWs from  
63 seven hospitals in Baku and collected information on sociodemographics, occupational exposure, and  
64 COVID-19 vaccination status. Participants completed weekly symptom questionnaires, those reporting

65 any respiratory symptom were tested for SARS-CoV-2 by RT-PCR. We administered questionnaires to  
66 PCR-positive participants 30 days post-symptom onset to obtain information about their illness course.  
67 Data on vaccination and SARS-CoV-2 PCR testing results were validated using national databases.

68 We restricted the analysis to participants eligible for booster doses according to the Azerbaijan  
69 government: those who had received PVS at least five months (150 days) prior. During January 1 –  
70 August 31, 2022, we estimated the rVE of a first booster compared to a PVS series against two  
71 outcomes: i) symptomatic PCR-confirmed SARS-CoV-2 infection (COVID-19) and ii) medically attended  
72 COVID-19, defined as an outpatient visit because of COVID-19. Participants were considered fully  
73 vaccinated 14 days after receiving their PVS and 7 days after receiving their booster dose. We assessed  
74 the effect of time since vaccination on rVE against symptomatic infection over the time intervals: 7–89,  
75 90–150 and  $\geq 150$  days following booster dose.

76 We evaluated rVE during the overall study period and separately for the period in which SARS-CoV-  
77 2 Omicron BA.1 and BA.2 variants were predominantly circulating (January 1–March 31, 2022), which  
78 we defined using whole genome sequencing data from study samples and publicly available data from  
79 GISAID (Figure S2) (9,11).

80 Relative VE was estimated as  $(1 - \text{adjusted hazard ratio}) * 100$ . Hazard ratios comparing vaccinated  
81 and unvaccinated participants were estimated using Cox proportional hazards models with vaccination  
82 as a time-varying exposure and a calendar timescale. Hospital location (urban or sub-urban) and  
83 previous SARS-CoV-2 infection were included in the model as fixed effects. Additional details about  
84 study methods are included in the supplemental material. The study was approved by the Azerbaijan  
85 and WHO Research Ethics Review Committees. All study participants provided written informed  
86 consent.

87 At the study start, there were 1367 participants (Figure S1). The median age was 48 (IQR: 39–57),  
88 and 1276 (93%) were female. Overall, 506 (37%) were nurses, 349 (26%) were physicians, and 512  
89 (37%) were other professions. Overall, 375 (27%) had received PVS, 939 (69%) had received a booster,  
90 30 (2%) received one vaccine dose, and 23 (2%) remained unvaccinated. Only participants who  
91 received CoronaVac vaccine were included in the analysis (Table 1). The median time from receiving  
92 the last vaccine dose until the start of follow-up was 66 days (IQR: 56–96) for booster dose and 150  
93 days (IQR: 150–187) for PVS. At the study end, 1186 (87%) participants had received a CoronaVac  
94 booster dose (Table S1).

95 During the study period, 74 participants (5%) had PCR-confirmed COVID-19, of whom 53 (72%) had  
96 been vaccinated with a booster dose and 17 (23%) with PVS. Most cases [66 (89%)] occurred between  
97 January and March 2022, mirroring the trends in COVID-19 incidence in Azerbaijan (Figure 1). Among  
98 the participants with PCR-confirmed SARS-CoV-2, 24 (32%) sought outpatient medical care. There were  
99 no emergency room visits, hospitalisations, or deaths among participants.

100 For the whole analysis period (January–August 2022), the rVE was 59% (95% CI: 24–78) against  
101 symptomatic infection and 78% (95% CI: 41–92) against medically attended infection. During the  
102 Omicron BA.1/BA.2-predominant period (January–March 2022), rVE of a CoronaVac booster was 60%  
103 (95% CI: 25–79) against symptomatic infection and 79% (95% CI: 44–92) against medically attended  
104 COVID-19 (Figure 2, Table 2). Relative VE against symptomatic infection was 50% (95% CI: -3–75) 7-89  
105 days post-booster, 67% (95% CI: 35–83) 90-149 days post-booster, and 48% (95% CI: -190–91) ≥150  
106 days post-booster during the whole study period. (Figure 2, Table 2).

107

108 **Conclusions**

109 Among HCWs in Azerbaijan, a CoronaVac booster dose offered additional protection against  
110 symptomatic infection and medically attended infection compared to CoronaVac PVS during an  
111 Omicron period. This protection, which lasted at least five months, occurred in a cohort that already  
112 had rates of prior infection approaching 70% in mid-2021 (9), highlighting the importance of the  
113 booster dose in reducing COVID-19 morbidity, even among HCWs with high rates of previous infection.  
114 The importance of the booster dose is relevant for the general population of Azerbaijan too, where  
115 COVID-19 PVS uptake is 47% and booster dose uptake is 34% (12).

116 Other studies have found variable rVE and absolute VE of a CoronaVac booster dose. A Brazilian  
117 study estimated a lower rVE of booster CoronaVac against symptomatic disease of 5% at 8-59 days  
118 after receipt; rVE subsequently declined to zero after 60 days in that study (5). Uncontrolled bias may  
119 have contributed to the low and negative estimates against symptomatic infection in that study (13).  
120 The same study estimated an rVE of booster CoronaVac against hospitalization of 47% during the same  
121 time period (5). In Hong Kong, in a mainly infection-naïve population, estimated absolute VE of  
122 CoronaVac booster against symptomatic BA.2 infection was 42% (3). In Brazil, in a population with  
123 higher seroprevalence, absolute VE of a CoronaVac booster dose was 9% (5); in another Brazilian study,  
124 CoronaVac booster dose absolute VE was 38% among persons with previous infection (7). CoronaVac  
125 booster absolute VE against severe disease during Omicron BA.1/BA.2 period was high in studies in  
126 both Hong Kong Special Administrative Region (85%) (4) and Brazil (74%) (5).

127 The strengths of our study include its prospective cohort design and close follow-up of  
128 participants. Moreover, this is one of few studies to evaluate inactivated COVID-19 vaccine in the WHO  
129 European Region. Our study also had limitations. The precision of rVE estimates was limited because of  
130 the low number of events. We could not measure absolute VE of a COVID-19 booster because of the

131 small number of unvaccinated participants. We were not powered to estimate VE against severe  
132 outcomes like hospitalization and death. Most infections occurred during Omicron BA.1/BA.2  
133 circulation, so VE estimates should be understood in that context.

134 In conclusion, our results highlight the additional preventive benefit of CoronaVac booster vaccine  
135 against symptomatic and medically attended infection and provide evidence to encourage uptake of  
136 future booster doses among HCWs and the general population in Azerbaijan.

137

138 Iris Finci is infectious disease epidemiologist. She is currently a consultant epidemiologist in WHO  
139 Regional Office for Europe coordinating COVID-19 and influenza vaccine effectiveness studies in  
140 European region. Her primary research interests include viral respiratory infections, tuberculosis and  
141 strengthening of disease surveillance.

142

#### 143 **Author contributions**

144 GH, MAK, NS, SM, and RP conceived the cohort study on which this analysis is based. MAK, LD, NS, SM,  
145 CJM, RP, GH, MYRC, and EK planned and implemented the study, including the development of study  
146 protocols, data quality checks, and acquisition of data. IF, NS and MAK conceived the article. IF and NS  
147 drafted the manuscript and performed the literature search. MYRC performed the data analysis with  
148 support from EK. SM, MYRC and EK directly accessed and verified the raw data and take responsibility  
149 for the integrity and accuracy of the analyses. BM and CD performed sequencing of study samples. All  
150 authors contributed to the interpretation of the results and critically revised the manuscript. All  
151 authors had full access to all the data reported in the study and accept responsibility to submit the  
152 paper for publication.

153

154 **Acknowledgements**

155 Javahir Suleymanova (World Health Organization, Country Office Azerbaijan), Alina Guseinova,  
156 Radu Cojocaru (World Health Organization, Regional Office for Europe, Denmark), Trent M. Herdman,  
157 Jason Doran (UK Field Epidemiology Training Programme, United Kingdom), Caleb Ward (US Centers  
158 for Disease Control, Georgia), Kathryn Lafond (US Centers for Disease Control, USA), Jörn Beheim-  
159 Schwarzbach, Victor M. Corman, and Terry C. Jones (Institute of Virology, Charité-Universitätsmedizin  
160 Berlin, corporate member of Freie Universität Berlin, Humboldt – Universität zu Berlin, and Berlin  
161 Institute of Health, Berlin, Germany; and German Centre for Infection Research (DZIF), partner site  
162 Charité, Berlin, Germany); Marta Valenciano and Alain Moren (Epiconcept, France).The Sorgular.az  
163 platform was developed by the Public Health and Reform Center of the Azerbaijan Ministry of Health  
164 with support from the United Nations Development Program and United Nations Population Fund.

165

166 **Disclaimer**

167 The findings and conclusions in this report are those of the author(s) and do not necessarily represent  
168 the views of the Centers for Disease Control and Prevention. The authors affiliated with the World  
169 Health Organization (WHO) are alone responsible for the views expressed in this publication and they  
170 do not necessarily represent the decisions or policies of the WHO.

171

172 **Financial statement**

173 This study was funded by The Task Force for Global Health and World Health Organisation Regional  
174 Office for Europe.



175

176 **Conflict of interest**

177 None of the authors have conflict of interest.

178

179 **References**

- 180 1. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths  
181 directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO  
182 European Region, December 2020 to November 2021. *Euro Surveill Bull Eur sur les Mal Transm*  
183 *= Eur Commun Dis Bull.* 2021 Nov;26(47).
- 184 2. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of  
185 COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis* [Internet].  
186 2022;22(9):1293–302. Available from: [http://dx.doi.org/10.1016/S1473-3099\(22\)00320-6](http://dx.doi.org/10.1016/S1473-3099(22)00320-6)
- 187 3. Tsang NNY, So HC, Cowling BJ, Leung G, Ip DKM. Effectiveness of BNT162b2 and CoronaVac  
188 COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron  
189 BA.2 in Hong Kong: a prospective cohort study. *Lancet Infect Dis* [Internet]. 2023;23(4):421–34.  
190 Available from: [http://dx.doi.org/10.1016/S1473-3099\(22\)00732-0](http://dx.doi.org/10.1016/S1473-3099(22)00732-0)
- 191 4. Wei Y, Jia KM, Zhao S, Hung CT, Mok CKP, Poon PKM, et al. Estimation of Vaccine Effectiveness  
192 of CoronaVac and BNT162b2 Against Severe Outcomes Over Time Among Patients With SARS-  
193 CoV-2 Omicron. *JAMA Netw Open.* 2023;6(2):1–13.
- 194 5. Ranzani OT, Hitchings MDT, de Melo RL, de França GVA, Fernandes C de FR, Lind ML, et al.  
195 Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters  
196 against Omicron in Brazil. *Nat Commun.* 2022;13(1):1–10.

- 197 6. Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, et al. Effectiveness of inactivated COVID-19 vaccines  
198 among older adults in Shanghai: retrospective cohort study. *Nat Commun.* 2023;14(1):2009.
- 199 7. Cerqueira-Silva T, de Araujo Oliveira V, Paixão ES, Florentino PTV, Penna GO, Pearce N, et al.  
200 Vaccination plus previous infection: protection during the omicron wave in Brazil. *Lancet Infect*  
201 *Dis.* 2022;22(7):945–6.
- 202 8. Johns Hopkins Bloomberg School of Public Health. International Vaccine Access Center (IVAC)  
203 [Internet]. 2023 [cited 2023 Jul 4]. Available from: [https://view-](https://view-hub.org/vaccine/covid/effectiveness-studies)  
204 [hub.org/vaccine/covid/effectiveness-studies](https://view-hub.org/vaccine/covid/effectiveness-studies)
- 205 9. Katz MA, Rojas Castro MY, Seyidov N, Herdman MT, Mehdiyev S, McKnight CJ, et al. The  
206 effectiveness of primary series CoronaVac vaccine in preventing COVID-19 illness: A prospective  
207 cohort study among healthcare workers in Azerbaijan, May–November 2021. *Influenza Other*  
208 *Respi Viruses* [Internet]. 2023;17(10):e13147. Available from:  
209 <https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.13147>
- 210 10. World Health Organization Regional Office for Europe. Cohort study to measure COVID-19  
211 vaccine effectiveness among health workers in the WHO European Region: guidance document.  
212 World Health Organization. Regional Office for Europe; 2021.
- 213 11. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data – from vision to reality.  
214 *Eurosurveillance* [Internet]. 2017;22(13). Available from:  
215 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.13.30494>
- 216 12. WHO Regional Office for Europe. WHO/Europe COVID-19 Vaccine Programme Monitor  
217 [Internet]. Available from: [https://worldhealthorg.shinyapps.io/EURO\\_COVID-](https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/)  
218 [19\\_vaccine\\_monitor/](https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/)

- 219 13. Bodner K, Irvine MA, Kwong JC, Mishra S. Observed negative vaccine effectiveness could be the  
 220 canary in the coal mine for biases in observational COVID-19 studies [Internet]. Vol. 131,  
 221 International Journal of Infectious Diseases. 2023. p. 111–4. Available from:  
 222 <https://pubmed.ncbi.nlm.nih.gov/33276180/>
- 223 14. World Health Organisation. WHO COVID-19 Dashboard [Internet]. 2023. Available from:  
 224 <https://covid19.who.int/>

225  
226  
227  
228  
229

230 **Table 1. Demographic and occupational characteristics of health care worker participants by vaccination**  
 231 **status on the first day of the follow-up period (n=1367), Azerbaijan, 2022**

	All Participants, N=1367	Unvaccinated, N=23	Partially vaccinated (one dose), N=30	Vaccinated with primary vaccine series (two doses), N=375	Vaccinated with booster dose (third dose), N=939
<b>Age, N=1367</b>					
Median (IQR)	48 (39-57)	51 (37-62.5)	43 (35-58.8)	47 (38-56)	49 (40-57)
<b>Age group, years, N=1367</b>					
20-29, n (%)	73 (5)	3 (13)	1 (3)	29 (8)	40 (4)
30-39, n (%)	290 (21)	6 (26)	12 (40)	84 (22)	188 (20)
40-49, n (%)	371 (27)	2 (9)	4 (13)	96 (26)	269 (29)
50-59, n (%)	416 (30)	4 (17)	8 (27)	110 (29)	294 (31)
60+, n (%)	217 (16)	8 (35)	5 (17)	56 (15)	148 (16)
<b>Sex, N=1367</b>					
M, n (%)	91 (7)	1 (4)	4 (13)	21 (6)	65 (7)
F, n (%)	1276 (93)	22 (96)	26 (87)	354 (94)	874 (93)
<b>Hospital, N=1367</b>					
Hospital 7, n (%)	269 (20)	4 (17)	2 (7)	40 (11)	223 (24)
Hospital 15, n (%)	122 (9)	0 (0)	1 (3)	8 (2)	113 (12)
Hospital 18, n (%)	204 (15)	1 (4)	3 (10)	56 (15)	144 (15)
Hospital 23, n (%)	95 (7)	3 (13)	6 (20)	29 (8)	57 (6)
Hospital 24, n (%)	191 (14)	6 (26)	5 (17)	82 (22)	98 (10)

Hospital 26, n (%)	359 (26)	2 (9)	10 (33)	107 (29)	240 (26)
Hospital 29, n (%)	127 (9)	7 (30)	3 (10)	53 (14)	64 (7)
<b>Hospital Location, N=1367</b>					
Urban, n (%)	517 (38)	7 (30)	9 (30)	146 (39)	355 (38)
Sub-urban, n (%)	850 (62)	16 (70)	21 (70)	229 (61)	584 (62)
<b>Occupation/Role in hospital, N=1367</b>					
Nurse or Midwife, n (%)	506 (37)	7 (30)	11 (37)	142 (38)	346 (37)
Medical Doctor, n (%)	349 (26)	7 (30)	8 (27)	101 (27)	233 (25)
Other, n (%)	512 (37)	9 (39)	11 (37)	132 (35)	360 (38)
<b>BMI, N=1367</b>					
Underweight or normal, n (%)	382 (28)	8 (35)	6 (20)	110 (29)	258 (27)
Overweight, n (%)	509 (37)	9 (39)	7 (23)	129 (34)	364 (39)
Obese, n (%)	476 (35)	6 (26)	17 (57)	136 (36)	317 (34)
<b>Smoking, N=1367</b>					
Currently smokes, n (%)	38 (3)	1 (4)	1 (3)	6 (2)	30 (3)
Never smokes, n (%)	1315 (96)	22 (96)	27 (90)	368 (98)	898 (96)
Smoked previously, n (%)	14 (1)	0 (0)	2 (7)	1 (<1)	11 (1)
<b>Any chronic condition, N=1367</b>					
No, n (%)	820 (60)	14 (61)	14 (47)	212 (57)	580 (62)
Yes, n (%)	547 (40)	9 (39)	16 (53)	163 (43)	359 (38)
<b>Number of chronic conditions, N=1367</b>					
0, n (%)	820 (60)	14 (61)	14 (47)	212 (57)	580 (62)
1, n (%)	383 (28)	4 (17)	10 (33)	104 (28)	265 (28)
≥2, n (%)	164 (12)	5 (22)	6 (20)	59 (16)	94 (10)
<b>Number of household members, N=1280</b>					
1-3, n (%)	500 (39)	12 (55)	10 (34)	138 (39)	340 (39)
4-5, n (%)	654 (51)	6 (27)	15 (52)	174 (49)	459 (52)
≥6, n (%)	126 (10)	4 (18)	4 (14)	41 (12)	77 (9)
<b>Hands on care, N=1367</b>					
No, n (%)	798 (58)	14 (61)	18 (60)	200 (53)	566 (60)
Yes, n (%)	569 (42)	9 (39)	12 (40)	175 (47)	373 (40)
<b>Previous COVID-19 PCR confirmed infection, N=1367</b>					
0, n (%)	1114 (81)	19 (83)	12 (40)	233 (62)	850 (91)
1, n (%)	253 (19)	4 (17)	18 (60)	142 (38)	89 (9)
<b>Delay between 2nd dose and start of follow-up (days), N=1314</b>					
Median (IQR)	305 (183-313)			150 (150-187)	309 (274-316)
<b>Delay between 3rd dose and start of follow-up (days), N=939</b>					
Median (IQR)	66 (56-92)				66 (56-92)
<b>COVID-19 vaccination status and vaccine brand at study period start, N=1367</b>					
Unvaccinated	23 (2)	23 (100)			
CoronaVac - 2 doses, n (%)	375 (27)			375 (100)	
CoronaVac - 3 doses, n (%)	939 (69)			939 (100)	
CoronaVac - 1 dose, n (%)	30 (2)	30 (100)			

232

233

**Table 2. Relative COVID-19 vaccine effectiveness of CoronaVac booster dose compared to CoronaVac primary vaccine series against symptomatic and medically attended SARS-CoV-2 infection during a period of Omicron and relative vaccine effectiveness against symptomatic SARS-CoV-2 infection by time since receiving booster dose, Azerbaijan, January 1 – August 31, 2022**

		N	Total person-time (days)	Symptomatic COVID-19 PCR-confirmed infections	Unadjusted HR	(95% CI)	Adjusted HR	(95% CI)	Relative vaccine effectiveness (%)	(95% CI)
Symptomatic infection	<b>Full period (Jan-Aug 2022)</b>	1306								
	2 doses, ≥150d from 2nd dose	386	19964	16						
	≥ 7d from 3rd dose	1184	232127	53	0.4	(0.7; 0.2)	0.4	(0.8; 0.2)	58.9	(24.3; 77.6)
	<b>BA.1/BA.2 Omicron period (Jan-Mar 2022)</b>	1253								
Symptomatic infection	2 doses, ≥150d from 2nd dose	334	9221	15						
	≥ 7d from 3rd dose	1142	82575	48	0.4	(0.7; 0.2)	0.4	(0.8; 0.2)	60.1	(24.7; 78.8)
	<b>Full period (Jan-Aug 2022)</b>	1306								
	2 doses, ≥150d from 2nd dose	386	19964	8						
Medically attended infection	≥ 7d from 3rd dose	1184	232127	15	0.2	(0.6; 0.1)	0.2	(0.6; 0.1)	77.7	(41.4; 91.5)
	<b>BA.1/BA.2 Omicron period (Jan-Mar 2022)</b>	1253								
	2 doses, ≥150d from 2nd dose	334	9221	7						
	≥ 7d from 3rd dose	1142	82575	13	0.3	(0.6; 0.1)	0.2	(0.6; 0.1)	79.1	(43.5; 92.3)
<b>Time since vaccination</b>										
Symptomatic infection	<b>Full period (Jan-Aug 2022)</b>	1306								
	2 doses, ≥150d from 2nd dose	386	19964	16	Reference		Reference		Reference	
	7-89 days since 3rd dose	929	42710	23	0.5	(1; 0.3)	0.5	(1; 0.2)	49.7	(-3.1; 75.4)
	90-149 days since 3rd dose	1104	59588	24	0.4	(0.7; 0.2)	0.3	(0.7; 0.2)	66.9	(35; 83.2)
	≥150 days since 3rd dose	1038	130127	6	0.5	(2.3; 0.1)	0.5	(2.9; 0.1)	48.2	(-190.3; 90.8)
	<b>BA.1/BA.2 Omicron period (Jan-Mar 2022)</b>	1253								
	2 doses, ≥150d from 2nd dose	334	9221	15	Reference		Reference		Reference	
	7-89 days since 3rd dose	890	31828	22	0.4	(0.9; 0.2)	0.4	(0.9; 0.2)	55.1	(9.6; 77.7)

90-149 days since 3rd dose	857	39158	24	0.4	(0.7; 0.2)	0.3	(0.7; 0.2)	67.1	(34.4; 83.5)
≥150 days since 3rd dose	464	11848	2	0.6	(3.2; 0.1)	0.7	(3.6; 0.1)	34.8	(-261.5; 88.2)

\*All rVE estimates were adjusted by hospital site (urban or suburban) and previous PCR-confirmed SARS-CoV-2 infection; HR – hazard ratio





Figure 1. Number of symptomatic PCR-confirmed SARS-CoV-2 positive healthcare workers by vaccination status and symptom onset, and number of SARS-CoV-2 cases in Azerbaijan (14), January-August 2022





**Figure 2. Relative vaccine effectiveness of a CoronaVac booster dose compared to CoronaVac primary series, Azerbaijan, 2022**

Left panel – symptomatic SARS-CoV-2 infection, total rVE (red) and stratified by time since vaccination (blue); Right panel – medically attended SARS-CoV-2 infection. Star (\*) indicates that the scale was cut off.